This compares with a net loss attributable to Arrowhead of $1.8 million, or $0.25 per share based on 7,182,628 weighted average shares outstanding, for the quarter ended June 30, 2011. The Company's net cash used in ope- rations for the first nine months of fiscal 2012 was $10.8 million, compared with $6.0 million for the first nine months of fiscal 2011. During fiscal 2012 third quarter the Company e.g. presented data for its Dynamic PolyConjugate(TM) (DPC) delivery platform for siRNA delivery inclu- ding its RNAi therapeutic candidate for the treatment of hepatitis B virus (HBV) at six scientific conferences, and completed all internal preclinical requirements and named a clinical candidate, ARC-520, for its HBV program. Arrowhead also announced the publication of a new study in the Journal of the American Diabetes Association demonstrating rapid improvement in pro-diabetic metabolic markers with its anti-obesity drug candidate, Adipotide(R), the dosing of the first patient in a Phase 1 clinical trial with the antiobesity drug candidate Adipotide(R) dosed additional patients in a Phase 1b study of CALAA-01.
Arrowhead Research Corporation has also entered into a securities purchase agreement with institutional and individual investors to raise gross proceeds of approximately $6.2 million. The placement con- sisted of the sale of 2.3 million shares of its common stock, and warrants to purchase 1.7 million shares of common stock. The stock and warrants will be sold in units, at a price of $2.76 per unit, with each unit consisting of one share of common stock and a war- rant to purchase 0.75 shares of common stock.
Arrowhead Research also entered into an agreement with Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic mono-clonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program. Arrowhead acquired this program through its purchase of Alvos Therapeutics in April 2012. Merck will bear the costs involved in evaluating the candidate.
http://www.arrowheadresearch.com
As part of its ongoing expansion, Asylum Research has appointed ATSL, Advanced Technological Solutions Ltd., as its exclusive distributor in Israel. ATSL managers have served nanotechnology and surface science markets in Israel for over 11 years and offer sales, service and technical support across the country. Asylum Research is a technology leader in atomic force and scanning probe microscopy (AFM/ SPM) for both materials and bioscience applications.
http://www.asylumresearch.com
Over the last few months, BASF has taken several strategic decisions to further strengthen its position in materials for high-performance batteries. Through acquisition of the US companies Ovonic Battery Company and Novolyte Technologies, purchase of Merck's electrolyte activities, conclusion of a license agreement to acquire the lithium iron phosphate technology (LFP) with the LiFePO4+C Licensing AG and participation in Sion Power, BASF has further improved its technology base and global market access for battery materials. Research and development activities have also been stepped up. “Most materials in lithium-ion batteries of the kind currently used in electric or hybrid cars are based
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105